Latest News

Astellas

Iktos Announces Agreement with Astellas for the use of its Synthesis-Aware Generative AI Platform

Astellas research teams will use Makya and Spaya to explore vast, synthesizable chemical space and connect molecular design directly to synthesis

Press releases and recognitions

Astellas
11.05.2026

Iktos Announces Agreement with Astellas for the use of its Synthesis-Aware Generative AI Platform

Iktos selected for JETRO Program to accelerate AI Drug Discovery expansion in Japan
08.25.2026

Iktos selected for JETRO Program to accelerate AI Drug Discovery expansion in Japan

New Patent Publication: Polycyclic MTHFD2 Inhibitors and Uses Thereof
07.23.2026

New Patent Publication: Polycyclic MTHFD2 Inhibitors and Uses Thereof

Press articles

Iktos featured by AWS Pioneers Project: Stories behind Europe's innovative breakthroughs

Iktos featured by AWS Pioneers Project: Stories behind Europe's innovative breakthroughs

Across Europe, innovators are reinventing what technology can do—for people and for the planet. From mapping the ocean to understanding how the human body works, these pioneers use cloud infrastructure, AI agents, and generative AI from AWS to solve humanity's toughest challenges, impacting millions of lives and protecting vital ecosystems.

Founded in 2016, Iktos is one of a handful of firms that saw the early potential of AI in drug discovery.
“It was kind of a revolution in our minds, saying that maybe you can use AI to optimise molecules,” explains Nicolas Do Huu, co-founder and CTO of Iktos.

Iktos featured by AWS Pioneers Project: Stories behind Europe's innovative breakthroughs
AWS Pioneers Project | 04.14.2026

Iktos featured by AWS Pioneers Project: Stories behind Europe's innovative breakthroughs

Aligning Artificial Intelligence and Laboratory Execution in Drug Discovery
Chemanager | 03.23.2026

Aligning Artificial Intelligence and Laboratory Execution in Drug Discovery

Drug discovery’s weakest link? Why synthesis is the critical bottleneck in the age of AI
Innovations in Pharmaceutical Technology | 12.16.2025

Drug discovery’s weakest link? Why synthesis is the critical bottleneck in the age of AI

Press Contact

PR Agency

PR Agency

For any communication need please contact PRLab
Mail :  dwain@prlab.co
Tel. : +31 202 443 748